Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial-Reference-Cited by-同舟云学术

Durability of Protection Afforded by Fewer Doses of the HPV16/18 Vaccine: The CVT Trial

Published:2017-08-28 Issue:2 Volume:110 Page:205-212
ISSN:0027-8874
Container-title:JNCI: Journal of the National Cancer Institute
language:en
Short-container-title:

Author:

Safaeian Mahboobeh¹,Sampson Joshua N.²,Pan Yuanji³,Porras Carolina⁴,Kemp Troy J.³,Herrero Rolando⁵,Quint Wim⁶,van Doorn Leen Jan⁶,Schussler John⁷,Lowy Douglas R.²,Schiller John²,Schiffman Mark T.²,Rodriguez Ana Cecilia⁴⁸,Gail Mitchell H.²,Hildesheim Allan²,Gonzalez Paula⁴,Pinto Ligia A.³,Kreimer Aimée R.²,Paula González,Herrero Rolando,Jiménez Silvia E.,Porras Carolina,Rodríguez Ana Cecilia,Hildesheim Allan,Kreimer Aimée R.,Lowy Douglas R.,Schiffman Mark,Schiller John T.,Sherman Mark,Wacholder Sholom,Pinto Ligia A.,Kemp Troy J.,Sidawy Mary K.,Quint Wim,van Doorn Leen-Jan,Struijk Linda,Palefsky Joel M.,Darragh Teresa M.,Stoler Mark H.,

Affiliation:

1. Roche Molecular Diagnostics, Pleasanton, CA

2. National Cancer Institute, National Institutes of Health, Bethesda, MD

3. HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD

4. Agencia Costarricense de Investigaciones Biomédicas (ACIB), formerly Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, San José, Costa Rica

5. Prevention and Implementation Group, International Agency for Research on Cancer, Lyon, France

6. DDL, Diagnostic Laboratory, Rijswijk, the Netherlands

7. Information Management Systems, Silver Spring, MD

8. Independent Consultant, San José, Costa Rica

Funder

National Cancer Institute (NCI)

National Institutes of Health

Publisher

Oxford University Press (OUP)

Subject

Cancer Research,Oncology

Link

http://academic.oup.com/jnci/article-pdf/110/2/205/25894819/djx158.pdf

Reference24 articles.

1. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008;Ferlay;Int J Cancer.,2010

2. Quadrivalent human papillomavirus vaccine: Recommendations of the Advisory Committee on Immunization Practices (ACIP);Markowitz;MMWR Recomm Rep.,2007

3. A review of human carcinogens—part B: Biological agents;Bouvard;Lancet Oncol.,2009

4. Global estimates of human papillomavirus vaccination coverage by region and income level: A pooled analysis;Bruni;Lancet Glob Health.,2016

5. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: A randomized clinical trial;Dobson;JAMA.,2013

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The Clinical Effectiveness of Single-Dose Human Papillomavirus Vaccination;Vaccines;2024-08-23

2. Cost-Effectiveness of Human Papillomavirus Vaccination in the UK: Two Versus Single-Dose of Nonavalent HPV Vaccination;American Journal of Preventive Medicine;2024-08

3. Efficacy and immunogenicity of a single dose of human papillomavirus vaccine compared to multidose vaccination regimens or no vaccination: An updated systematic review of evidence from clinical trials;Vaccine: X;2024-08

4. Prevención y detección precoz del cáncer cervicouterino;Revista Médica Clínica Las Condes;2024-03

5. The clinical effectiveness of one-dose vaccination with an HPV vaccine: A meta-analysis of 902,368 vaccinated women;PLOS ONE;2024-01-05